Zipalertinib (CLN-081)

“In the United States, approximately 16% of patients with NSCLC harbor EGFR mutations,” (opens the source at this quote in a new tab)CopyFlag

“with insertions at exon 20 accounting for up to 12% of these mutations.” (opens the source at this quote in a new tab)CopyFlag

“In the U.S., approximately 16% of NSCLC cases harbor EGFR mutations, with insertions at exon 20 accounting for 12% of those mutations.” (opens the source at this quote in a new tab)CopyFlag

“NSCLC is a common form of lung cancer and up to 4% of all cases globally have EGFR ex20ins.” (opens the source at this quote in a new tab)CopyFlag

“NSCLC is a common form of lung cancer and up to 4% of all cases have EGFR exon 20 insertions, which makes them the third most common EGFR mutation subtype.” (opens the source at this quote in a new tab)CopyFlag

“Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLOS ONE. 2021;16(3): e0247620.” (opens the source at this quote in a new tab)CopyFlag

“Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLOS ONE. 2021;16(3):e0247620.” (opens the source at this quote in a new tab)CopyFlag

“The frequency of Exon 20ins mutation ranged from 0.1% to 4% of all NSCLC cases and 1% to 12% of all EGFR mutations.” (opens the source at this quote in a new tab)CopyFlag

“The Exon 20ins mutation is the third most common type of EGFR mutation in NSCLC, after Exon 19 deletions and Exon 21 L858R point mutations” (opens the source at this quote in a new tab)CopyFlag

“the US (0.5%–2.6% among all NSCLC cases and 5%–12% of EGFRm tumors).” (opens the source at this quote in a new tab)CopyFlag

“Approximately 30% of non-small cell lung cancer (NSCLC) tumors harbor a mutation in the epidermal growth factor receptor (EGFR) gene, with geographical variation in rates reported to be highest in Asia (38%) and lowest in Europe (14%)” (opens the source at this quote in a new tab)CopyFlag

“Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology. 2018 Jul 5;13(10):1560–1568.” (opens the source at this quote in a new tab)CopyFlag

“Comprehensive genomic profiling (CGP) performed on 14,483 NSCLC cases in the course of clinical care identified 2,251 cases with EGFR mutations, 263 of these cases were EGFRex20ins, representing 12% of all EGFR-mutant NSCLC and 1.8% of all NSCLC cases tested.” (opens the source at this quote in a new tab)CopyFlag